GET DAILY SIGNALSAveanna Healthcare Holdings (AVAH) Analyst Targets Point to +22.5% Upside
Key Takeaways
- The central target of $15 is the arithmetic mean of eight verified, current analyst price targets, and implies roughly 22.5% upside from the latest price near $12.24.
- Individual targets used span a relatively narrow range of $13 to $16, with most firms clustered at $14 to $16.
- The strongest supports are Medicaid and preferred-payer rate gains, double-digit adjusted EBITDA growth, and steady deleveraging.
- The biggest risks are a large debt load, reimbursement uncertainty, caregiver-labor costs, and a recent post-earnings pullback in the shares.
- For more on this ticker's latest developments, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- To screen ideas and monitor changing trends, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Aveanna Healthcare Holdings (AVAH), a pediatric and adult home-care provider, is covered by a concentrated but active group of sell-side analysts. The eight targets reviewed here carry firm names and recent dates: Barclays at $15 (October 2026), Raymond James at $15 (September 2026), J.P. Morgan at $15 (September 2026), Truist at $15 (August 2026), RBC Capital at $16 (August 2026), Deutsche Bank at $16 (August 2026), BMO Capital at $14 (August 2026), and UBS at $13 (August 2026). Their simple average works out to about $14.88, which rounds to a central target of $15. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The low-to-high range is narrow, from $13 to $16, and ratings span Neutral (J.P. Morgan, Truist, UBS), Overweight/Buy (Barclays, RBC, Deutsche Bank, BMO), and Strong Buy (Raymond James). The near-unanimity around the $15 level reflects a common thesis: improving reimbursement, preferred-payer expansion, and margin discipline. The range also shows honest disagreement about how much the improved earnings profile is already reflected in the price after a sharp run.
Current Market Position and Path Toward the Target
The stock traded near $12.24 on the day of its third-quarter report, down about 6.5% from a prior close of $13.09, even though results beat estimates. Reaching $15 would require a move of roughly 22.5%, which is best described as substantial. The stock has already more than doubled from its 52-week low of $5.93, and its 52-week high of $14.71 sits just under the central target.
The path toward $15 depends less on revenue growth than on margin conversion and leverage. Third-quarter revenue rose 11.8% to $695.5 million, adjusted EBITDA climbed 25% to $100.1 million, and net income jumped to $45.5 million from $14.1 million a year earlier. Full-year 2026 revenue guidance was raised to more than $2.695 billion and adjusted EBITDA guidance to more than $374 million. The stock still pulled back, however, because the revised outlook's midpoint was roughly in line with consensus rather than ahead of it. From what I see, this setup warrants close monitoring of execution on the margin side.
What Could Support a Move Toward the Target
Several verified factors underpin the bullish case. Aveanna has secured eight state rate enhancements year to date and is pursuing a significant California private-duty-nursing rate investment beginning January 2027, alongside expanded preferred-payer agreements that reached 65% of private-duty managed-care volumes. Adjusted EBITDA margin improved to 14.4% of revenue in the quarter, and corporate expense discipline continues to convert revenue growth into earnings at a faster rate. Free cash flow of $141.2 million over nine months supports deleveraging, which analysts cite as the key to a higher valuation multiple. The home- and community-based care market is structurally growing, with demand driven by aging demographics and a shift toward lower-cost care settings.
What Could Prevent the Target From Being Reached
The risks are equally concrete. Aveanna still carried about $1.52 billion in total indebtedness against roughly $197.8 million in cash as of early October 2026, leaving the equity sensitive to interest rates and any earnings stumble. Reimbursement is politically and administratively uncertain, and the California rate increase remains subject to budget and regulatory follow-through. Caregiver hiring and retention, wage inflation, and a narrow guidance beat that disappointed investors all weigh on sentiment. Insider selling and the exit of large legacy holders have also been notable. If margin progress stalls or leverage stays elevated, valuation compression could outweigh earnings growth.
Technical Levels and Market Structure
The 52-week high of $14.71 acts as the first meaningful resistance zone, essentially coinciding with the central $15 target and making that area a psychological and technical ceiling. Below, the stock's sharp rally off the $5.93 low has left limited nearby support, with the post-earnings dip toward $12.15 marking a near-term level to watch. A sustained move above $15 would represent a breakout to new highs, while a loss of the low-$12 area could signal a deeper retracement of the recent advance.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month forward horizon, though firms do not state identical timeframes. Investors should monitor quarterly earnings and guidance, the pace of additional state rate enhancements and preferred-payer signings, the California rate decision, adjusted EBITDA margin progression, and debt reduction. Changes in interest rates and any shifts in reimbursement policy are also relevant to both the valuation multiple and the balance-sheet story. I’m watching this closely as the next few quarters will clarify whether the fundamentals can overcome the balance-sheet concerns.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders spot changing trends and monitor positions more efficiently than manual screening allows. For those following a name like AVAH, such signals can offer a complementary, data-driven view alongside fundamental and analyst research. In my own process, these signals have helped flag potential inflection points that pure fundamentals might miss.
Using Tickeron AI Tools for Deeper Research
When analyzing names like AVAH, I often turn to Tickeron’s suite of AI tools to cross-check analyst views against broader market patterns. The AI Daily Buy/Sell Signals platform stands out for its ability to process real-time data and highlight shifts that might not be obvious from earnings releases alone. It has become a regular part of my workflow for tracking momentum alongside the fundamental drivers discussed here.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVAH sees MACD Histogram just turned negative
AVAH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 38 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AVAH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
AVAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on AVAH as a result. In 80 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
AVAH moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AVAH crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVAH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 141 of 177 cases where AVAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AVAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.043) is normal, around the industry mean (204.532). P/E Ratio (9.962) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.223) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement